Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Australian Patient Treated With DC Bead LUMI™, the First Commercially Available Radiopaque Drug-Eluting Bead PR Newswire LONDON, January 21, 2019 LONDON, January 21, 2019 /PRNewswire/ -- BTG plc...
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims PR Newswire PHILADELPHIA, January 8, 2019 PHILADELPHIA, January 8, 2019 /PRNewswire/ -- Distributed ledger technology is a game...
BTG Announces National Reimbursement for TheraSphere® in France PR Newswire LONDON, December 21, 2018 LONDON, December 21, 2018 /PRNewswire/ -- An estimated 500 patients per year in France could...
BTG Announces Global Launch of the ICEfx™ Cryoablation System PR Newswire LONDON, September 20, 2018 LONDON, September 20, 2018 /PRNewswire/ -- The ICEfx™ Cryoablation system is a compact and...
ELEVATE Study Aims to Improve Selection Criteria and Outcomes for Patients with Severe Emphysema Treated with the PneumRx™ Endobronchial Coil System PR Newswire LONDON, June 11, 2018 LONDON, June...
BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC Based on experience with 1000 patients over 15 years, the largest single-centre prospective...
New Consensus Guidelines Provide Specific Recommendations for Use of Voraxaze® in Patients with Delayed Methotrexate Clearance PR Newswire LONDON, November 16, 2017 LONDON, November 16, 2017...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
